Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Vical Slumps, Cytomegalovirus Vaccine Fails In Phase II Study

Published 09/20/2016, 04:16 AM
Updated 07/09/2023, 06:31 AM

Vical Incorporated (NASDAQ:VICL) and partner Astellas Pharma, Inc. (OTC:ALPMY) announced disappointing top-line data from a phase II study on their experimental cytomegalovirus (CMV) vaccine candidate, ASP0113, in kidney transplant patients. Vical’s shares plunged 22.3% on the news.

The randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of ASP0113 in CMV-seronegative kidney transplant recipients, receiving an organ from a CMV-seropositive donor. Data showed that the study failed to meet the primary endpoint, which was the proportion of patients having CMV viremia through one year after first injection of the vaccine.

In addition, the secondary endpoints including CMV-associated disease and CMV-specific antiviral therapy were found to be similar in both treatment groups, as evaluated by an independent, blinded Adjudication Committee.

Although the safety profiles were found to be similar among treatment groups, local injection site reactions were more common in the ASP0113 arm. Additional detailed data from the study is expected to be revealed at an upcoming scientific congress.

Considering that there exists a significant unmet need for treatments addressing CMV, a herpes virus infection, the phase II study results fails to impress.

VICAL INC Price

Vical, however, plans to continue to move with pivotal phase III study on ASP0113 in hematopoietic cell transplant (HCT) recipients, also in collaboration with Astellas. Data from the study is expected in the fourth quarter of 2017. We note that ASP0113 has Orphan Drug status in the both the U.S. and Europe for the prevention of CMV disease in solid organ transplant and HCT recipients.

We remind investors that this is not the first time that Vical has faced a pipeline setback. In 2013, the company had terminated the development of an intratumoral cancer immunotherapy, Allovectin, following negative phase III study results. Further, in 2015, neither its monovalent nor bivalent genital herpes vaccine had met the primary endpoint in a phase I/II study.

Meanwhile, Vical is conducting a phase I study on VL-2397 for the treatment of invasive fungal infections, including invasive aspergillus. We note that Vical had in-licensed the candidate in Mar 2015 from Astellas under an exclusive worldwide license agreement.

Vical carries a Zacks Rank #2 (Buy). A couple of favorably placed stocks in the health care sector are Anika Therapeutics, Inc. (NASDAQ:ANIK) and ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

VICAL INC (VICL): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.